Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice

Journal of Neuroscience

Volumn 29, Issue 7, 2009, Pages 1977-1986

  Meilandt, William J ^a,b   Cisse, Moustapha ^a,b   Ho, Kaitlyn ^a   Wu, Tiffany ^a   Esposito, Luke A ^a,b   Scearce Levie, Kimberly ^a,b   Cheng, Irene H ^a,b   Yu, Gui Qiu ^a   Mucke, Lennart ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

Author keywords

A *56; Amyloid; Hippocampus; Memory; Premature mortality; Water maze

Indexed keywords

AMYLOID PRECURSOR PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; OLIGOMER;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; IN VIVO STUDY; LEARNING; MEMORY; MOUSE; NEOCORTEX; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; LEARNING DISORDERS; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEPRILYSIN; POLYMERS; SENILE PLAQUES;

EID: 60849097262     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2984-08.2009     Document Type: Article

References (68)

1. Apostolova LG, Cummings JL (2008) Neuropsychiatric manifestations in mild cognitive impairment: a systematic review ofthe literature. Dement Geriatr Cogn Disord 25:115-126.
2. c) immunocytochemistry and expression ofthe green fluorescent protein reporter gene under control of the bovine PrP gene promoter in the mouse brain. J Comp Neurol 473:244-269.
3. Belzung C, Griebel G (2001) Measuring normal and pathological anxietylike behaviour in mice: a review. Behav Brain Res 125:141-149.
4. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403.
5. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26:645-654.
6. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282:23818-23828.
7. Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ (2000) Purified recombi-nant insulin-degrading enzyme degrades amyloid β-protein but does not promote its oligomerization. Biochem J 351:509-516.
8. Chin J, Palop J, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Mucke L (2005a) Increasing Fyn kinase activity in APP transgenic mice impairs Arc expression induced by novel environment exposure. Soc Neurosci Abstr 31:324.325.
9. Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L (2005b) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25:9694-9703.
10. Choi DS, Wang D, Yu GQ, Zhu G, Kharazia VN, Paredes JP, Chang WS, Deitchman JK, Mucke L, Messing RO (2006) PKCe increases endothe-lin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA 103:8215-8220.
11. Congdon EE, Kim S, Bonchak J, Songrug T, Matzavinos A, Kuret J (2008) Nucleation-dependent tau filament formation: The importance of dimer-ization and an estimation of elementary rate constants. J Biol Chem 283:13806-13816.
12. Deipolyi AR, Fang S, Palop JJ, Yu G-Q, Wang X, Mucke L (2008) Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 29:253-266.
13. Farlow MR, Cummings JL (2007) Effective pharmacologic management of Alzheimer's disease. Am J Med 120:388-397.
14. Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ (2007) Loss of neprily-sin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171:241-251.
15. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112-2117.
16. Gan L, Mucke L (2008) Paths of convergence: sirtuins in aging and neuro-degeneration. Neuron 58:10-14.
17. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligo-meric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422.
18. Hama E, Shirotani K, Iwata N, Saido TC (2004) Effects of neprilysin chi-meric proteins targeted to subcellular compartments on amyloid β pep-tide clearance in primary neurons. J Biol Chem 279:30259-30264.
19. Hellström-Lindahl E, Ravid R, Nordberg A (2008) Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Aβ levels. Neurobiol Aging 29:210-221.
20. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G (1995) Age-related CNS disorder and early death in transgenic FVB/N mice over-expressing Alzheimer amyloid precursor proteins. Neuron 15:1203-1218.
21. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N (2006) Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281:17941-17951.
22. Iijima K, Chiang HC, Hearn SA, Hakker I, Gatt A, Shenton C, Granger L, Leung A, Iijima-Ando K, Zhong Y (2008) Aβ42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One 3:e1703.
23. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Aβ by nepri-lysin. Science 292:1550-1552.
24. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC (2002) Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70:493-500.
25. Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC (2004) Presynaptic localization ofnepri-lysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 24:991-998.
26. Iwata N, Higuchi M, Saido TC (2005) Metabolism of amyloid-β peptide and Alzheimer's disease. Pharmacol Ther 108:129-148.
27. Kanemitsu H, Tomiyama T, Mori H (2003) Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350:113-116.
28. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG (2004) Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apo-lipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 24:3801-3809.
29. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ (2008) Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28:4231-4237.
30. Kobayashi DT, Chen KS (2005) Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 4:173-196.
31. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Syn-aptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24:10191-10200.
32. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis ofβ-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40:1087-1093.
33. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid- β protein assembly in the brain impairs memory. Nature 440:352-357.
34. Lhatoo SD, Sander JW (2005) Cause-specific mortality in epilepsy. Epilepsia 46 (Suppl 11):36-39.
35. Manson J, West JD, Thomson V, McBride P, Kaufman MH, Hope J (1992) The prion protein gene: a role in mouse embryogenesis? Development 115:117-122.
36. Marks N, Berg MJ (2003) APP processing enzymes (secretases) as therapeutic targets: insights from the use of transgenics (Tgs) and transfected cells. Neurochem Res 28:1049-1062.
37. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23:1992-1996.
38. Mayford M, Mansuy IM, Muller RU, Kandel ER (1997) Memory and behavior: a second generation of genetically modified mice. Curr Biol 7:R580-R589.
39. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phin-ney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P (2006) Cyclo-hexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801-808.
40. Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L (2008) Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 28:5007-5017.
41. Moechars D, Lorent K, Van Leuven F (1999a) Premature death in trans-genic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience 91:819-830.
42. Moechars D, Dewachter I, Lorent K, Reversé D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Van Den Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999b) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274:6483-6492.
43. Mouri A, Zou LB, Iwata N, Saido TC, Wang D, Wang MW, Noda Y, Na-beshima T (2006) Inhibition of neprilysin by thiorphan (i.c.v.) causesan accumulation of amyloid β and impairment of learning and memory. Behav Brain Res 168:83-91.
44. 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neu-rosci 20:4050-4058.
45. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51:703-714.
46. Ognibene E, Middei S, Daniele S, Adriani W, Ghirardi O, Caprioli A, Laviola G (2005) Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behav Brain Res 156:225-232.
47. Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J, Masliah E, Mucke L (2003) Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci USA 100:9572-9577.
48. Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768-773.
49. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55:697-711.
50. Poirier R, Wolfer DP, Welzl H, Tracy J, Galsworthy MJ, Nitsch RM, Mohajeri MH (2006) Neuronal neprilysin overexpression is associated with attenuation of Aβ -related spatial memory deficit. Neurobiol Dis 24:475-483.
51. Roberson ED, Mucke L (2006) 100 years and counting: prospects for defeating Alzheimer's disease. Science 314:781-784.
52. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754.
53. Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Es-posito L, Mucke L, Masliah E (2005) High β-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-β levels: implications for the treatment of Alzheimer's disease. J Biol Chem 280:32957-32967.
54. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of transgenic mice and humans with Alzheimer's disease. J Biol Chem 270:28257-28267.
55. Sakurada C, Yokosawa H, Ishii S-I (1990) The degradation of somatostatin bysynaptic membrane ofrat hippocampus is initiated byendopeptidase-24.11. Peptides 11:287-292.
56. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32:177-180.
57. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875.
58. Shankar GM, Li S, Mehta T, Garcia-Munoz A, Shepardson NE, Smith I, Brett F, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid β-protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory. Nat Med 14:837-842.
59. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC (2001) Ne-prilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive en-dopeptidases. J Biol Chem 276:21895-21901.
60. Solà C, Tusell JM, Serratosa J (1999) Comparative study of the distribution of calmodulin kinase II and calcineurin in the mouse brain. J Neurosci Res 57:651-662.
61. Tagami S, Okochi M, Fukumori A, Jiang J, Yanagida K, Nakayama T, Mori-hara T, Tanaka T, Kudo T, Takeda M (2008) Processes of beta-amyloid and intracellular cytoplasmic domain generation by presenilin/gamma-secretase. Neurodegener Dis 5:160-162.
62. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol 572:477-492.
63. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20:3937-3946.
64. Turner AJ, Isaac RE, Coates D (2001) The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23:261-269.
65. Van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Cotman CW, Cunningham DD (1989) Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid β-protein precursor. Nature 341:546-549.
66. Walsh DM, Selkoe DJ (2007) A beta oligomers-a decade of discovery. J Neurochem 101:1172-1184.
67. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oli-gomerization ofamyloid β-protein begins intracellularlyin cells derived from human brain. Biochemistry 39:10831-10839.
68. Weber P, Metzger D, Chambon P (2001) Temporally controlled targeted somatic mutagenesis in the mouse brain. Eur J Neurosci 14:1777-1783.